Abstract

Research Article

Age as a Predictor of Time to Response for Patients Undergoing Medical Management of Endometrial Cancer

M Larissa Weirich*, Carolyn R Larkins, Wendy Y Craig, Emily Meserve, Terri Febbraro, Jason Lachance and Leslie S Bradford

Published: 04 October, 2023 | Volume 6 - Issue 4 | Pages: 150-159

Objective: To explore the pathologic response rate to primary progesterone treatment in patients with Endometrial Intraepithelial Neoplasia (EIN) and early-stage endometrioid-type Endometrial Adenocarcinoma (EAC).
Methods: Retrospective chart data were collected for patients with either EIN or EAC receiving primary progesterone treatment between 2015 and 2022. The presence of complete or partial response, time to response, and other demographic and treatment factors were recorded to determine independent predictors of response to progestin treatment.
Results: In total, 112 women who were diagnosed with EIN or EAC were treated with upfront progestin therapy, of whom 79 had sufficient follow-up to assess response. Fifty patients (63%) responded, of whom 10 (20%) ultimately relapsed. Response was more robust among patients with EIN (79%, n = 33) compared with patients who had cancer (46%, n = 17). The median time to respond was 5.8 months overall. Diagnosis of EIN, younger age at diagnosis, and any pathologic evidence of progesterone effect were all predictors of treatment response. Younger patients had a significantly shorter time to partial or complete response with a median time to response of 5.9 months in patients ≤ 45 and 13.8 months in patients > 45. 
Conclusion: Our study demonstrated a lower overall response rate (63%) than reported in previous studies, especially for patients with cancer (46%). Younger patients had a significantly shorter time to respond than older patients. Pathologic progesterone effect observed at any time during treatment was a significant predictor of treatment response regardless of diagnosis and could serve as an early predictor of response to therapy.

Read Full Article HTML DOI: 10.29328/journal.cjog.1001144 Cite this Article Read Full Article PDF

Keywords:

Endometrial cancer; Progesterone treatment; Endometrial intraepithelial neoplasia; Medical management

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PMID: 35020204.
  2. Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1145-1153. doi: 10.1055/a-1545-4279. Epub 2021 Oct 6. PMID: 34629493; PMCID: PMC8494521.
  3. The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. Obstet Gynecol. 2015 May;125(5):1272-1278. doi: 10.1097/01.AOG.0000465189.50026.20. PMID: 25932867.
  4. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Feb;16(2):170-199. doi: 10.6004/jnccn.2018.0006. PMID: 29439178.
  5. Affinito P, Di Carlo C, Di Mauro P, Napolitano V, Nappi C. Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone. Maturitas. 1994 Dec;20(2-3):191-8. doi: 10.1016/0378-5122(94)90016-7. PMID: 7715472.
  6. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008 Aug;139(2):169-75. doi: 10.1016/j.ejogrb.2008.02.022. Epub 2008 Apr 28. PMID: 18440693.
  7. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N, Hiura M, Sakamoto A, Tsuda H, Fukunaga M, Kamura T. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007 Jul 1;25(19):2798-803. doi: 10.1200/JCO.2006.08.8344. PMID: 17602085.
  8. Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010 Jan;28(1):81-90. doi: 10.1055/s-0029-1242998. Epub 2010 Jan 26. PMID: 20104432; PMCID: PMC4767501.
  9. Maine Cancer Registry. “2022 Maine Cancer Snapshot.” Maine Cancer Registry, based on November 2021 NPCR-CSS data submission: Maine Department of Health and Human Services, Maine Center for Disease Control and Prevention.
  10. Baker WD, Pierce SR, Mills AM, Gehrig PA, Duska LR. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecol Oncol. 2017 Jul;146(1):34-38. doi: 10.1016/j.ygyno.2017.04.006. Epub 2017 Apr 18. PMID: 28427775.
  11. Hubbs JL, Saig RM, Abaid LN, Bae-Jump VL, Gehrig PA. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol. 2013 Jun;121(6):1172-1180. doi: 10.1097/AOG.0b013e31828d6186. PMID: 23812449.
  12. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 Feb;224(2):191.e1-191.e15. doi: 10.1016/j.ajog.2020.08.032. Epub 2020 Aug 15. PMID: 32805208; PMCID: PMC7855308.
  13. Chiva L, Lapuente F, González-Cortijo L, Carballo N, García JF, Rojo A, Gonzalez-Martín A. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008 Nov;111(2 Suppl):S101-4. doi: 10.1016/j.ygyno.2008.07.056. Epub 2008 Sep 18. PMID: 18804267.
  14. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004 Oct;95(1):133-8. doi: 10.1016/j.ygyno.2004.06.045. PMID: 15385122.
  15. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002 Apr;186(4):651-7. doi: 10.1067/mob.2002.122130. PMID: 11967486.
  16. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007 Jul;31(7):988-98. doi: 10.1097/PAS.0b013e31802d68ce. PMID: 17592264.
  17. Baker W, Pelkofski E, Duska L. Levonorgestrel intrauterine device (IUD) treatment of complex atypical hyperplasia and grade 1 endometrioid endometrial cancer in postmenopausal women. Gynecologic Oncology. 2014; 133:
  18. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 Jan;131(1):109-116. doi: 10.1097/AOG.0000000000002390. PMID: 29215513; PMCID: PMC5739955.
  19. Li M, Guo T, Cui R, Feng Y, Bai H, Zhang Z. Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis. Cancer Manag Res. 2019 May 6;11:4005-4021. doi: 10.2147/CMAR.S194607. PMID: 31190979; PMCID: PMC6512613.
  20. Kitson S, Ryan N, MacKintosh ML, Edmondson R, Duffy JM, Crosbie EJ. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD012513. doi: 10.1002/14651858.CD012513.pub2. Update in: Cochrane Database Syst Rev. 2023 Mar 27;3:CD012513. PMID: 29388687; PMCID: PMC6491136.
  21. Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, Walker G, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecol Oncol. 2021 Apr;161(1):143-151. doi: 10.1016/j.ygyno.2021.01.029. Erratum in: Gynecol Oncol. 2021 Aug;162(2):526. PMID: 33762086.
  22. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012 May;125(2):477-82. doi: 10.1016/j.ygyno.2012.01.003. Epub 2012 Jan 11. PMID: 22245711.
  23. Mitsuhashi A, Habu Y, Kobayashi T, Kawarai Y, Ishikawa H, Usui H, Shozu M. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol. 2019 Nov;30(6):e90. doi: 10.3802/jgo.2019.30.e90. PMID: 31576686; PMCID: PMC6779615.
  24. Yang BY, Gulinazi Y, Du Y, Ning CC, Cheng YL, Shan WW, Luo XZ, Zhang HW, Zhu Q, Ma FH, Liu J, Sun L, Yu M, Guan J, Chen XJ. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG. 2020 Jun;127(7):848-857. doi: 10.1111/1471-0528.16108. Epub 2020 Feb 16. PMID: 31961463.
  25. Acosta-Torres S, Murdock T, Matsuno R, Beavis AL, Stone RL, Wethington SL, Levinson K, Grumbine F, Ferriss JS, Tanner EJ, Fader AN. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates. Gynecol Oncol. 2020 May;157(2):348-356. doi: 10.1016/j.ygyno.2020.02.008. Epub 2020 Feb 19. PMID: 32085863.

Figures:

Similar Articles

  • Patient, disease and surgeon predictors of successful bilateral sentinel lymph node mapping for endometrial cancer: A retrospective, multicenter analysis
    Mary Towner, Kaylee Underkoffler, Anze Urh, Katina Robison and Richard G Moore* Mary Towner,Kaylee Underkoffler,Anze Urh,Katina Robison,Richard G Moore*. Patient, disease and surgeon predictors of successful bilateral sentinel lymph node mapping for endometrial cancer: A retrospective, multicenter analysis. . 2022 doi: 10.29328/journal.cjog.1001111; 5: 072-079
  • Ectopic Pregnancy Risk Factors Presentation and Management Outcomes
    Awadalla Abdelwahid Suliman*, Hajar Suliman Ibrahim Ahmed, Kabbashi Mohammed Adam Hammad, Ibtehal Jaffer Youssef Alsiddig, Mohamed Abdalla Elamin Abdelgader, Abdallah Omer Elzein Elhag and Safa Mohamed Ibrahim Awadalla Abdelwahid Suliman*, Hajar Suliman Ibrahim Ahmed, Kabbashi Mohammed Adam Hammad, Ibtehal Jaffer Youssef Alsiddig, Mohamed Abdalla Elamin Abdelgader, Abdallah Omer Elzein Elhag, Safa Mohamed Ibrahim. Ectopic Pregnancy Risk Factors Presentation and Management Outcomes. . 2023 doi: 10.29328/journal.cjog.1001143; 8: 143-149
  • Age as a Predictor of Time to Response for Patients Undergoing Medical Management of Endometrial Cancer
    M Larissa Weirich*, Carolyn R Larkins, Wendy Y Craig, Emily Meserve, Terri Febbraro, Jason Lachance and Leslie S Bradford M Larissa Weirich*, Carolyn R Larkins, Wendy Y Craig, Emily Meserve, Terri Febbraro, Jason Lachance, Leslie S Bradford. Age as a Predictor of Time to Response for Patients Undergoing Medical Management of Endometrial Cancer. . 2023 doi: 10.29328/journal.cjog.1001144; 6: 150-159
  • Women's Perceptions of Medical Treatment Versus Surgical Management of First-trimester Miscarriage
    Azza Mustafa Elzein, Hajar Suliman Ibrahim Ahmed, Awadalla Abdelwahid Suliman*, Siddig Omer M Handay, Gamar Bushra Omer and Sahar Ali Musa Azza Mustafa Elzein, Hajar Suliman Ibrahim Ahmed, Awadalla Abdelwahid Suliman*, Siddig Omer M Handay, Gamar Bushra Omer, Sahar Ali Musa. Women's Perceptions of Medical Treatment Versus Surgical Management of First-trimester Miscarriage. . 2023 doi: 10.29328/journal.cjog.1001150; 6: 193-200

Recently Viewed

Read More

Most Viewed

Read More

Help ?